According to a new report, published by KBV research, The Global Leukemia Therapeutics Market size is expected to reach $11.7 billion by 2029, rising at a market growth of 6.0% CAGR during the forecast period.
The Chemotherapy segment is showcasing a CAGR of 6.8% during (2023 - 2029). Chemotherapy is a medication therapy that targets the body's rapidly proliferating cells by killing them with potent poisons. Since cancer cells grow and multiply far quicker than the majority of body cells, chemotherapy is most frequently used to treat cancer. The increasing number of leukemia cases is the main reason driving the growth of the chemotherapy segment.
The Hospital Pharmacies segment acquired maximum revenue share in the Global Leukemia Therapeutics Market by Distribution Channel in 2022 thereby, achieving a market value of $6.8 billion by 2029. Hospitals serve as the main treatment setting, and patients use them to diagnose medical conditions and administer various therapies, which has led to an increase in hospital pharmacies. In addition, a greater number of patients are now seeking treatment in hospitals due to increased awareness of leukemia and its available treatments, which is causing the hospital pharmacies segment to expand.
The Acute Lymphocytic Leukemia segment has shown the growth rate of 6.2% during (2023 - 2029). Acute lymphocytic leukemia (ALL) is a malignancy that develops from the lympholastic precursor white blood cells in the bone marrow. The main factor causing this type of cancer is an excessive generation of malignant lymphoblasts. The production of normal cells like platelets and red blood cells (RBC) is typically suppressed by lymphoblasts, which are overproduced and constantly multiplying in the bone marrow in ALL cancer patients. This causes damage to the bone marrow. Leukemia cells are another name for these lymphoblasts.
The North America market dominated the Global Leukemia Therapeutics Market by Region in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $4.6 billion by 2029. The Europe market is exhibiting a CAGR of 5.8% during (2023 - 2029). Additionally, The Asia Pacific market would showcase a CAGR of 6.6% during (2023 - 2029).
Full Report: https://www.kbvresearch.com/leukemia-therapeutics-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Gilead Sciences, Inc., Bristol Myers Squibb Company, Sanofi S.A., AbbVie, Inc., Teva Pharmaceuticals Industries Ltd., Lupin Limited, Amgen, Inc., Takeda Pharmaceutical Company Limited, Pfizer, Inc. and Novartis AG.
By Drug Class
By Distribution Channel
By Type
By Geography
Companies Profiled
Unique Offerings 
